Revelation Biosciences Inc

[Available On-Demand]
Revelation is a clinical stage life sciences company focused on the development of immunologic based therapies for the prevention and treatment of disease. The Company has several product candidates in development. REVTx 99, the lead therapeutic candidate, is an intranasal immunomodulator for the early treatment of SARS CoV 2 infection. An expansion of REVTx 99 therapeutic indications is planned, targeting early treatment and prevention of respiratory viral infection such as influenza A or B, parainfluenza, and respiratory syncytial virus. REVTx 200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx 200 is based on the same technology used in REVTx-99. Revelation is also developing REVDx 501, a rapid point of care diagnostic that can be used to detect any respiratory viral infection regardless of virus type without the need for specialized instrumentation
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Lead Product in Development:
REVTx-99
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
Chairman
Revelation Biosciences Inc